<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564534</url>
  </required_header>
  <id_info>
    <org_study_id>P/2019/417</org_study_id>
    <nct_id>NCT04564534</nct_id>
  </id_info>
  <brief_title>Impact of Pre-procedure Cognitive Status on Outcome at 3 Months After Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>TAVI-Geriatrie</acronym>
  <official_title>Impact of Pre-procedure Cognitive Status on Outcome at 3 Months After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to investigate the relationship between cognitive status pre-procedure, and&#xD;
      clinical outcomes at 3 months in patients undergoing transcatheter aortic valve implantation&#xD;
      (TAVI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to investigate the relationship between cognitive status pre-procedure, as&#xD;
      assessed using the Montreal Cognitive Assessment (MoCA) administered on a tablet, and&#xD;
      clinical outcomes at 3 months as assessed by the VARC2 criteria, in patients undergoing&#xD;
      transcatheter aortic valve implantation (TAVI)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause death</measure>
    <time_frame>through 30 days after the TAVI procedure</time_frame>
    <description>Safety outcome at 3 months as assessed by the VARC2 criteria: all-cause death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>through 30 days after the TAVI procedure</time_frame>
    <description>Safety outcome at 30 days as assessed by the VARC2 criteria: stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>life-threatening bleed</measure>
    <time_frame>through 30 days after the TAVI procedure</time_frame>
    <description>Safety outcome at 30 days as assessed by the VARC2 criteria: life-threatening bleed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined VARC2 safety outcome</measure>
    <time_frame>through 30 days after the TAVI procedure</time_frame>
    <description>Safety criteria (within 30 days of the procedure) include all-cause death; stroke; life-threatening bleed; renal insufficiency; coronary artery obstruction requiring intervention; major vascular complication; valve dysfunction.&#xD;
Clinical Efficacy criteria (30 days to 3 months after the procedure) include: all-cause death; stroke; re-admission for valve-rela</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined VARC2 efficacy outcome</measure>
    <time_frame>through 30 days after the TAVI procedure</time_frame>
    <description>Clinical Efficacy criteria (30 days to 3 months after the procedure) include: all-cause death; stroke; re-admission for valve-related symptoms or worsening heart failure; NYHA Class III or IV; valve-related dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time required for MoCA</measure>
    <time_frame>At the time of MoCA completion</time_frame>
    <description>Length of time required to administer the MoCA test using a tablet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological parameters pre-procedure</measure>
    <time_frame>pre-procedure</time_frame>
    <description>Blood count; prothrombin; TCA; fibrinogen; INR; creatinine; CRP; BNP; TSH; HbA1c; troponin; albumin; GDF15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between MoCA score and each component of the VARC2</measure>
    <time_frame>At 3 months after TAVI procedure</time_frame>
    <description>The relationship between the MoCA and each individual component of the VARC2 will be investigated in bivariable analysis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Study cohort</arm_group_label>
    <description>Adult (&gt;18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up.&#xD;
The MoCA will be administered by trained professionals with MoCA certification.&#xD;
Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MoCA cognitive assessment</intervention_name>
    <description>cognitive assessment using the validated MoCA test administered via an application on an iPad</description>
    <arm_group_label>Study cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be taken and centrifuged, and plasma will be aliquoted and frozen at&#xD;
      -80Â°Celsius for analysis of growth differentiation factor (GDF) 15.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with aortic stenosis and a confirmed indication for TAVI, scheduled to undergo&#xD;
        TAVI and who perform their pre-TAVI work-up in our centre will be invited to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or over&#xD;
&#xD;
          -  Scheduled to undergo TAVI&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
          -  Able to understand French&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects under legal guardianship or other legal protection&#xD;
&#xD;
          -  subjects with documented severe dementia&#xD;
&#xD;
          -  subjects with anticipated poor compliance&#xD;
&#xD;
          -  subjects unable to understand French sufficiently well to perform the MoCA test&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  subjects within the exclusion period of another study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Schiele, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francois U Schiele, MD, PhD</last_name>
    <phone>+33381668539</phone>
    <email>francois.schiele@univ-fcomte.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fiona Ecarnot</last_name>
    <phone>+33381668539</phone>
    <email>fiona.ecarnot@Univ-fcomte.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Ecarnot</last_name>
      <phone>+33381668539</phone>
      <email>fiona.ecarnot@Univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Charles Monnin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francois Schiele, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain Chopard, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transcatheter aortic valve replacement</keyword>
  <keyword>aortic stenosis</keyword>
  <keyword>cognitive status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

